Last reviewed · How we verify
OFF Dopaminergic Medication
At a glance
| Generic name | OFF Dopaminergic Medication |
|---|---|
| Sponsor | James Liao |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Connectomic Guided DBS for Parkinson's Disease (NA)
- Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
- Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease (PHASE1)
- Markers of Disease Progression and Gait Within the Parkinsonian Population (NA)
- Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
- Psychological Effects of Levodopa in Parkinson's Disease (NA)
- REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis (NA)
- SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OFF Dopaminergic Medication CI brief — competitive landscape report
- OFF Dopaminergic Medication updates RSS · CI watch RSS
- James Liao portfolio CI